TitledA Randomized, Placebo-Controlled Clinical Trial Demonstrating Safety & Efficacy of enXtra® in Healthy Adults, the 12-week double-blind, randomized, placebo-controlled, parallel-group study was conducted on adults who reported moderate caffeine consumption. The subjects were randomized to receive either enXtra, enXtra plus caffeine or placebo. The finding: enXtra, either alone or in combination with caffeine, delivered acute and consistent improvement in alertness.OmniActivesaid this strengthens earlier findings supporting the nootropic benefits of enXtra. Additionally, there were no safety concerns with long-term use, and the study suggest that subjects do not have to take increasing doses of enXtra to achieve a similar effect.
"With more than 50% of consumers reporting that their energy levels have worsened in the last 10 years, the market for healthy energy will continue to grow in the supplement space," said Arti Shah, Executive Vice President of Global Marketing at OmniActive. Shah added that enXtra, which is suitable for RTDs, sports nutrition and workout formulas, energy bars, snacks, gummies, fruit juices, chewing gum and stick packs, provides formulators with a unique solution for natural, safe and clinically tested ingredients to stand out in a crowded marketplace.
"The latest study demonstrates our commitment to support on-trend claims with credible science for our global customers," added Jayesh Chaudhary, Founder and CEO of ENovate Biolife. "Whether it's using computerized Attention Network Test, molecular docking studies, or assessing longer-term cardiogenic safety, we rely on cutting-edge research tools that are setting new benchmarks in our industry."
